All Releases
 |
Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals
Jan 31, 2012
|
62.5 KB |
|
| |
SPI-2012, Spectrum's Third Biological Drug, Is a Long-Acting GCSF
That Utilizes Hanmi's Proprietary Platform Technology, LAPSCOVERY™;
SPI-2012 Could Have Potential Advantages for More Rapid and
Profound Granulocyte Recovery in Patients with Chemotherapy Induced
Neutropenia, A Mul...
|
|
Spectrum Pharmaceuticals Strengthens Commercial Operations
Jan 27, 2012
|
15.2 KB |
|
| |
Spectrum Expects Fourth Quarter 2011 Revenues to Be Equal to or
Greater Than Third Quarter 2011;
The Company Anticipates Filing Two New Drug Applications (NDAs) in
2012;
In Preparation of Potential Launch of Apaziquone and Belinostat in
2013, and to Bolst...
|
|
Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN®
Jan 25, 2012
|
15.8 KB |
|
| |
Spectrum's Commercial Footprint Expands Beyond the U.S.;
Irrevocable License From Bayer Healthcare Leverages Spectrum's
Existing Clinical, Regulatory and Marketing Investments;
Spectrum Will Continue To Advance ZEVALIN's Clinical Development
Program And Will Now Be ...
|
|
ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in "CANCER", the Journal of the American Cancer Society
Jan 23, 2012
|
19.7 KB |
|
| |
Two Year Overall Survival Rate Was 91% for Z-BEAM vs. 62% for BEAM
Alone (p= 0.05);
Publication in "Cancer" Shows Increasing Recognition and Importance
of ZEVALIN in Improving Outcomes in the Treatment of Refractory
High-Risk Lymphomas;
ZEVALIN Has the Po...
|
|
Spectrum Pharmaceuticals to Present at the J. P. Morgan Healthcare Conference
Jan 4, 2012
|
12.9 KB |
|
| |
Corporate Overview to be Presented on Thursday, January 12th
at 11am Pacific Time at the 30th Annual
Conference in San Francisco, California
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology company with
fully integrated comme...
|
|
Impressive ZEVALIN® Data Highlighted at 53rd Annual Meeting of the American Society of Hematology; Spectrum to Increase Clinical Efforts to Expand ZEVALIN Indications
Dec 12, 2011
|
78.2 KB |
|
| |
Groundbreaking ZEVALIN Data in Follicular Non-Hodgkin's Lymphoma
Presented from a Phase 2 Study in Newly Diagnosed Patients Who Have
Never Received Any Prior Treatment for Their Disease
93% Overall Response Rate and 82% Complete Response Rate
Observed
...
|
|
Multifaceted Repositioning Campaign for ZEVALIN® Unveiled at ASH 2011, Following Recent FDA Approval to Remove Bioscan Requirement
Dec 12, 2011
|
18.9 KB |
|
| |
Unique and Multifaceted ZEVALIN Repositioning Campaign Unveiled at
the 2011 Annual Meeting of the American Society of Hematology (ASH) in
San Diego, California;
This Follows FDA's Decision on November 20th,
2011 To Remove Bioscan Requirement
...
|
|
Spectrum Pharmaceuticals Affirms Strong Patent Protection for FUSILEV® (levoleucovorin) Through December 31, 2019
Dec 9, 2011
|
15.0 KB |
|
| |
FDA Granted FUSILEV® "Orphan Drug"
Designation and Market Exclusivity Through 2018
FUSILEV Therapeutic Composition Patent Expires at the end of
December 2019
Company Has Filed a Patent Term Extension Application Potentially
Extending Patent Protectio...
|
|
Spectrum Pharmaceuticals Announces 19 ZEVALIN Presentations at the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego, California, December 10-13, 2011
Dec 9, 2011
|
23.9 KB |
|
| |
Five Abstracts Selected By the Lymphoma Review Committee for Oral
Presentation
ZEVALIN Is Currently Approved By The FDA And Marketed By Spectrum
Pharmaceuticals In The United States For:
Treatment Of Patients With Previously Untreated Follicular
...
|
|
Spectrum Pharmaceuticals to Present at the Oppenheimer & Co. 22nd Annual Healthcare Conference
Dec 7, 2011
|
12.0 KB |
|
| |
Corporate Overview to Be Presented on Wednesday, December 14th
at 2:45pm Eastern Time
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary foc...
|
|
Spectrum Pharmaceuticals Files IND Application with U.S. FDA for SPI-014
Dec 5, 2011
|
14.6 KB |
|
| |
SPI-014, a Novel Lanthanum-Based Compound, is Being Developed as a
Treatment for the Increased Blood Levels of Phosphorus Seen in End
Stage Renal Disease
Based on Proprietary Nanoparticle Technology, Spectrum's Small,
Easy-to-Swallow Tablets Are Designed to Improve Phosphate Binding;
...
|
|
Spectrum Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell on Tuesday, November 29, 2011
Nov 28, 2011
|
13.2 KB |
|
| |
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS:SPPI) today announced that Rajesh C.
Shrotriya, MD, Chairman, Chief Executive Officer, and President, has
been invited to chair the opening ceremonies and ring the Nasdaq Stock
Market opening bell on Tuesday, November 29, 2011.
...
|
|
FDA Approves the Removal of the Bioscan Requirement for ZEVALIN® Treatment
Nov 21, 2011
|
18.6 KB |
|
| |
The Removal of the Bioscan Requirement Was Approved by the FDA
After the Market Close on November 18, 2011, and is Effective
Immediately
A Major Revision to the Package Insert Will Permit Simplified
Access to ZEVALIN® for Patients with Follicular
Non-Hodgkin Lymphoma
...
|
|
Spectrum Pharmaceuticals to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
Nov 9, 2011
|
12.0 KB |
|
| |
Corporate Overview to Be Presented on Wednesday, November 16th
at 2:00pm Eastern Time
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary foc...
|
|
Spectrum Pharmaceuticals, Inc. Reports Strongest Financial Position in Company History: Record Revenues, Profits, and Cash Generated from Operations for the Three- and Nine-Month Periods Ended September 30, 2011
Oct 28, 2011
|
30.6 KB |
|
| |
$209 Million In Cash, Cash Equivalents, Investments and Receivables
as of September 30, 2011
Record Performance in the Three- and Nine-Month 2011:
Total Revenues of $51 Million and $140 Million, Respectively,
Vs. $17 Million and $40...
|
|
Spectrum Pharmaceuticals Announces Date and Time for Its Third Quarter and Nine-Month 2011 Financial Results Conference Call
Oct 24, 2011
|
12.1 KB |
|
| |
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary focus in hematology and oncology, today announced the date and
time for its third quarter and nine-month period ended September 30,
...
|
|
Spectrum Pharmaceuticals Strengthens Commercial Operations with Appointment of Brian Holzer MD, MBA as Executive Director of Brand Management
Sep 28, 2011
|
13.9 KB |
|
| |
Biotechnology Professional with Significant Experience in
Hematology/Oncology Strategy and Marketing
Joins Spectrum from Amgen, Where He Was the Director of United
States Strategy and Operations for the NEUPOGEN®/Neulasta®,
Multi-Billion Dollar Worldwide Franchise
...
|
|
Spectrum Pharmaceuticals Completes Enrollment in the Belinostat Pivotal Trial for Relapsed/Refractory Peripheral T-Cell Lymphoma
Sep 26, 2011
|
14.9 KB |
|
| |
Registrational Trial Under a Special Protocol Assessment
Granted Fast Track and Orphan Drug Designation by FDA
On Track to File New Drug Application in 2012
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a b...
|
|
Spectrum Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
Sep 23, 2011
|
11.8 KB |
|
| |
Corporate Overview to Be Presented on Wednesday, September 28th
at 10:00 am London Time
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
...
|
|
Spectrum Pharmaceuticals Receives Approximately $25 Million from Warrant Exercise
Sep 20, 2011
|
12.6 KB |
|
| |
Nearly $160 Million in Cash, Cash Equivalents, and Investments as
of September 16, 2011, Up From Approximately $119 Million in Cash,
Cash Equivalents, and Investments as of June 30, 2011
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnolo...
|
|
|
